A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ENLARGE-Lung
- Sponsors Bristol-Myers Squibb
- 30 Mar 2017 Planned End Date changed from 1 Aug 2023 to 15 Aug 2023.
- 30 Mar 2017 Planned primary completion date changed from 1 Aug 2023 to 15 Aug 2023.
- 07 Oct 2016 Planned End Date changed from 1 Dec 2023 to 1 Aug 2023.